Jeffrey M. Liebmann
Fondateur chez American Glaucoma Society Foundation
Profil
Jeffrey M.
Liebmann is the founder of New York Glaucoma Research Institute, American Glaucoma Society Foundation.
He is currently the Vice-Chairman & Director-Glaucoma Division at Columbia University Irving Medical Center, Director at Glaucoma Foundation, Director at Sustained Nano Systems LLC, Director at Galimedix Therapeutics, Inc. (Maryland), President at World Glaucoma Association, Advisor at Infocus Capital Partners, and President at New York Society For Clinical Ophthalmology.
He was formerly the President of American Glaucoma Society.
Postes actifs de Jeffrey M. Liebmann
| Sociétés | Poste | Début |
|---|---|---|
Sustained Nano Systems LLC
 Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Directeur/Membre du Conseil | - |
Galimedix Therapeutics, Inc. (Maryland)
 Galimedix Therapeutics, Inc. (Maryland) Medical/Nursing ServicesHealth Services Galimedix Therapeutics, Inc. is an ophthalmic pharmaceutical company based in Kensington, MD. Galimedix is focused on developing innovative treatments for various neurodegenerative diseases. The company's lead product, GAL-101, has shown promising results in treating these diseases. The company was founded by Chris Parsons, Andrew Leonard Pearlman, Alexander Gebauer. | Directeur/Membre du Conseil | - |
| Columbia University Irving Medical Center | Directeur/Membre du Conseil | - |
| World Glaucoma Association | President | - |
| Glaucoma Foundation | Directeur/Membre du Conseil | - |
| New York Society For Clinical Ophthalmology | President | - |
| New York Glaucoma Research Institute | Fondateur | - |
Infocus Capital Partners
 Infocus Capital Partners Investment ManagersFinance InFocus Capital Partners (InFocus Capital Partners) is a venture capital firm founded in 2016 by Rob Rothman and Ron Weiss. The firm is headquartered in Jericho, New York. | Consultant / Advisor | - |
| American Glaucoma Society Foundation | Fondateur | - |
Anciens postes connus de Jeffrey M. Liebmann
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░ ░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
| World Glaucoma Association | |
American Glaucoma Society
 American Glaucoma Society Investment Trusts/Mutual FundsMiscellaneous The American Glaucoma Society supports glaucoma specialists and scientists through the advancement of education and research. | Miscellaneous |
| Glaucoma Foundation | |
Infocus Capital Partners
Infocus Capital Partners Investment ManagersFinance InFocus Capital Partners (InFocus Capital Partners) is a venture capital firm founded in 2016 by Rob Rothman and Ron Weiss. The firm is headquartered in Jericho, New York. | Finance |
Sustained Nano Systems LLC
Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Commercial Services |
Galimedix Therapeutics, Inc. (Maryland)
Galimedix Therapeutics, Inc. (Maryland) Medical/Nursing ServicesHealth Services Galimedix Therapeutics, Inc. is an ophthalmic pharmaceutical company based in Kensington, MD. Galimedix is focused on developing innovative treatments for various neurodegenerative diseases. The company's lead product, GAL-101, has shown promising results in treating these diseases. The company was founded by Chris Parsons, Andrew Leonard Pearlman, Alexander Gebauer. | Health Services |
| Columbia University Irving Medical Center | |
| New York Society For Clinical Ophthalmology | |
| New York Glaucoma Research Institute | |
| American Glaucoma Society Foundation |
